title: Lipophilic statin use and risk of breast cancer subtypes.
abstract: OBJECTIVE
  Statins are widely used and of high interest as potential chemopreventive agents for cancer. Preclinical studies suggest that lipophilic statins have anticancer properties targeting hormone receptor (HR)-negative breast cancer. Few epidemiologic studies have investigated the relationship between lipophilic statin use and risk for breast cancer, stratified by HR status. We conducted a large case-control study within Kaiser Permanente of Northern California (KPNC) to determine whether chronic use of lipophilic statins is associated with decreased risk of HR-negative breast cancer or other breast cancer subtypes.
  
  
  METHODS
  We identified 22,488 breast cancer cases diagnosed from 1997 to 2007, and 224,860 controls matched to cases based upon birth year and duration of KPNC pharmacy coverage. Use of lipophilic statins was ascertained using the comprehensive electronic pharmacy records of KPNC.
  
  
  RESULTS
  We found no association between lipophilic statin use (≥2 y versus never) and overall breast cancer risk (odds ratio(adj), 1.02; 95% CI, 0.97-1.08) in conditional logistic regression models adjusted for oral contraceptive and hormone therapy use. Women who used lipophilic statins did not have a decreased risk of HR-negative breast cancer (odds ratio(adj), 0.98; 95% CI, 0.84-1.14) nor altered risk of HR-positive disease (odds ratio(adj), 1.03; 95% CI, 0.97-1.10). Furthermore, lipophilic statin use was not associated with risk of any of the intrinsic subtypes, luminal A, luminal B, human epidermal growth factor receptor 2 positive/estrogen receptor negative, or triple negative.
  
  
  CONCLUSIONS
  Our results do not support an association of lipophilic statin use with the risk for breast cancer in general or with risks of HR-negative or other breast cancer subtypes specifically.
  
  
  CONCLUSIONS
  These findings do not confirm previous reports of a possible preventive association.
authors: Cancer Prevention Fellowship Program, National Cancer Institute, NIH, Bethesda, Maryland, USA.
authors: Stephan
authors: S
authors: Woditschka
authors: Laurel A
authors: LA
authors: Habel
authors: Natalia
authors: N
authors: Udaltsova
authors: Gary D
authors: GD
authors: Friedman
authors: Weiva
authors: W
authors: Sieh
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology* / Q000378:metabolism / Q000517:prevention & control; D002140:California / Q000453:epidemiology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016015:Logistic Models; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone